Ann: ePAT Pain Assessment App Secures Regulatory Clearance, page-156

expected news is easy to say in hindsight...

however i have found many stocks miss their stated timelines on delivery of news for instance RAP in achieving FDA approval was spoken about being in 2016?

MXC missed a few early milestones on its pharma acquisition but got it rolled out in the end.

I am sure other people have other examples.....

for EPT management in the prospectus late last year to set out their milestones and to date hit each one as stated is a testament to the quality running the company....

so we may have high standards and expect them to hit milestones but the broader market reality is few dont as planned......

also i think there have already been a few extras along the way, the IBM relationship, the peer review journal article, the quicker than anticipated regulatory approval.....